Aarti Pharmalabs closed FY26 with standalone revenue of ₹1,797.6 Cr, a modest 1.5% YoY rise.

However, profit after tax (PAT) saw a 31.5% decline to ₹176.2 Cr, with diluted EPS at ₹19.42. International sales contributed 54% of the year's revenue.

Strategic growth is driven by significant capacity expansions.

Xanthine derivatives capacity is set to increase from 5,000+ MTPA to over 9,000 MTPA by Q1 FY27, targeting a 20-25% global market share.

The Atali greenfield project's Phase 1, largely operational and resolving initial challenges, will be fully functional by June.

These expansions, along with the Tarapur brownfield project, represent a combined CAPEX of ₹610 Cr.

In Q4 FY26, the CDMO/CMO segment delivered its highest-ever quarterly revenue of ₹155 Cr.

Looking ahead, management plans R&D investments in TIDES (Peptides & Oligonucleotides) in FY27 and aims for 15-18% Revenue & EBITDA CAGR over the next 3-4 years.

FY27 CAPEX is expected to be around ₹400 Cr, similar to FY26. Geopolitical tensions led to rising input costs, impacting API/Intermediates margins.